AbCellera Investor Conference Presentation Deck

BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 17 2 ANTIBODIES FOR COVID-19 There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone. bamlanivimab + etesevimab Bamlanivimab alone and together with etesevimab has been used to treat more than 535,000 patients, potentially preventing 20,000+ hospitalizations and 10,000 deaths. Effective against Delta variant* bebtelovimab Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab. Effective against variants of concern, including the Delta variant* * Shown to be effective against the Delta variant in preclinical studies

View entire presentation